The DOI matches its Crossref record.
Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.
Abstract
Increased expression of P-glycoprotein is associated with multidrug resistance (MDR) in many cell lines. Significant levels of P-glycoprotein have been detected in a number of human tumors. The purpose of this study was to determine whether P-glycoprotein expression correlates with both response to chemotherapy and prognosis in soft tissue sarcoma of childhood. In a retrospective study, biopsy samples from 30 cases of rhabdomyosarcoma (RMS) and undifferentiated sarcoma (US) treated at The Hospital for Sick Children in Toronto were analyzed using a semiquantitative immunohistochemical procedure. P-glycoprotein was detected in nine patients, four at diagnosis, and five at subsequent biopsy. All nine patients relapsed after a clinical response (complete [CR] 55%, partial [PR] 45%) to chemotherapy. Twenty of 21 patients with consistently P-glycoprotein-negative tumors received chemotherapy and they all responded clinically (CR 80%, PR 20%). Only one of these 20 patients has relapsed. The probability of relapse-free survival was significantly different (P less than .000000012) in chemotherapy-treated patients whose tumors contained detectable levels of P-glycoprotein (n = 9), compared with those whose tumors contained no detectable P-glycoprotein (n = 20). The overall probability of survival was also significantly different in these two groups (P less than .0000267). Both relapse-free and overall survivals remained statistically different in the two groups of patients when analyzed by the log-rank method, after adjustment for differences in stages and sites. The incidence of other adverse prognostic factors in the two groups, for example, younger and older ages, low pretreatment lymphocyte counts, large tumors, and unfavorable histology were not significantly different. Thus, detectable P-glycoprotein appears to be an important adverse prognostic factor in children with soft tissue sarcoma, and consistent absence of the protein is associated with a favorable prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Multidrug resistance: molecular mechanisms and clinical relevance
Ling, V. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051053 · Cited by 522
Self-citationP-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma
Chan, H. S. L., Haddad, G., Thorner, P. S., DeBoer, G., Lin, Y. P., Ondrusek, N., Yeger, H., & Ling, V. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252304 · Cited by 441
Self-citationVery important pharmacogene summary
Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283385a1c · Cited by 436
Chemotherapy With Focal Therapy Can Cure Intraocular Retinoblastoma Without Radiotherapy
Gallie, B. L. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140521001 · Cited by 416
An overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome
Baldini, N., Scotlandi, K., Barbanti-Bròdano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332103 · Cited by 399
Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells
Bebawy, M., Combes, V, Lee, E., Jaiswal, R., Gong, J., Bonhoure, A., & Grau, G. E. R. (2009) · Leukemia · doi:10.1038/leu.2009.76 · Cited by 322
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
Mechetner, E. B., & Roninson, I. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5824 · Cited by 316
ABC-transporters: implications on drug resistance from microorganisms to human cancers
Lage, H. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00203-6 · Cited by 298
Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V., & Limtrakul, P.-N. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01224-8 · Cited by 291
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
Sikic, B. I. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051055 · Cited by 277
Metadata
- Authors
- Chan, H. S., Thorner, P. S., Haddad, G., & Ling, V
- Venue
- Journal of Clinical Oncology
- Published
- 1990-04
- Volume
- 8
- Issue
- 4
- Pages
- 689-704
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104733808
- Cited by
- 451
- References
- 0
- FWCI
- 66.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.